Cargando…

Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement

BACKGROUND: Base excision repair (BER) pathway is a DNA repair pathway that is important in carcinogenesis and in response to DNA-damaging chemotherapy. XRCC1 is one of important molecular markers for BER. So far, the role of XRCC1 polymorphisms with clinical outcomes of advanced NSCLC treated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Dan-Juan, Xiao, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526237/ https://www.ncbi.nlm.nih.gov/pubmed/28743242 http://dx.doi.org/10.1186/s12885-017-3487-y

Ejemplares similares

Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis
por: Zhang, Ningning, et al.
Publicado: (2020)

XRCC3 Thr241Met Polymorphism and Clinical Outcomes of NSCLC Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis
por: Shen, Xiao-yong, et al.
Publicado: (2013)

ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy
por: Liblab, Salisa, et al.
Publicado: (2020)

XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis
por: Zhang, Zhuo, et al.
Publicado: (2018)

Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy
por: Yuan, Zhengrong, et al.
Publicado: (2015)

Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients
por: Liu, Di, et al.
Publicado: (2017)

Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC
por: Peng, Wenpan, et al.
Publicado: (2021)

PRISMA statement and PROSPERO
por: Bernardo, Wanderley Marques
Publicado: (2017)

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
por: Nishio, Makoto, et al.
Publicado: (2021)

XRCC3 Thr241Met Is Associated with Response to Platinum-Based Chemotherapy but Not Survival in Advanced Non-Small Cell Lung Cancer
por: Qiu, Mantang, et al.
Publicado: (2013)

Prognostic significance of galectin‐3 expression in patients with resected NSCLC treated with platinum‐based adjuvant chemotherapy
por: Kusuhara, Seiichiro, et al.
Publicado: (2021)

A Meta-Analysis for Association of XRCC1, XRCC2 and XRCC3 Polymorphisms with Susceptibility to Thyroid Cancer
por: Mandegari, Mohammad, et al.
Publicado: (2021)

Reporting Quality of Systematic Reviews and Meta-Analyses of Otorhinolaryngologic Articles Based on the PRISMA Statement
por: Peters, Jeroen P. M., et al.
Publicado: (2015)

Quality of reporting of systematic reviews and meta-analyses in emergency medicine based on the PRISMA statement
por: Nawijn, Femke, et al.
Publicado: (2019)

Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients
por: Yin, Ji-Ye, et al.
Publicado: (2012)

PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews
por: Rethlefsen, Melissa L., et al.
Publicado: (2021)

PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews(*)
por: Rethlefsen, Melissa L., et al.
Publicado: (2021)

Cinobufotalin injection combined with chemotherapy for the treatment of advanced NSCLC in China: A PRISMA-compliant meta-analysis of 29 randomized controlled trials
por: Zhang, Fan, et al.
Publicado: (2019)

How to properly use the PRISMA Statement
por: Sarkis-Onofre, Rafael, et al.
Publicado: (2021)

The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma
por: Cheng, Xiao-Dong, et al.
Publicado: (2009)

Effect of XPC polymorphisms on the response to platinum-based chemotherapy: a meta-analysis
por: Xie, Chenyao, et al.
Publicado: (2019)

Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis
por: Chen, Juan, et al.
Publicado: (2016)

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
por: Moher, David, et al.
Publicado: (2009)

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement
por: Moher, David, et al.
Publicado: (2009)

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
por: Moher, David, et al.
Publicado: (2009)

Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review
por: Afifah, Nadiya Nurul, et al.
Publicado: (2020)

Traditional herbal medicine combined with first-line platinum-based chemotherapy for advanced non-small-cell lung cancer: A PRISMA-compliant systematic review and meta-analysis
por: Jin, Hayun, et al.
Publicado: (2021)

ERCC1 and XRCC1 but not XPA single nucleotide polymorphisms correlate with response to chemotherapy in endometrial carcinoma
por: Chen, Liang, et al.
Publicado: (2016)

Association of XRCC1, XRCC2 and XRCC3 Gene Polymorphism with Esophageal Cancer Risk
por: Kaur, Jagjeet, et al.
Publicado: (2020)

Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy
por: Alvisi, Maria Francesca, et al.
Publicado: (2020)

A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy
por: Xue, Ping, et al.
Publicado: (2022)

The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC
por: WANG, YA-DI, et al.
Publicado: (2011)

Compliance of systematic reviews in ophthalmology with the PRISMA statement
por: Lee, Seon-Young, et al.
Publicado: (2017)

Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial
por: Yang, James Chih-Hsin, et al.
Publicado: (2021)

Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
por: Tang, Ning, et al.
Publicado: (2017)

Establishing a Prediction Model for the Efficacy of Platinum—Based Chemotherapy in NSCLC Based on a Two Cohorts GWAS Study
por: Xiao, Qi, et al.
Publicado: (2023)

OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC
por: Hao, Yanzhang, et al.
Publicado: (2014)

The Roles of EXO1 and RPA1 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: He, Jia, et al.
Publicado: (2022)

Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration
por: Welch, Vivian, et al.
Publicado: (2015)

The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy
por: Zou, Ting, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8utq8hjk5tgmd7dan7v6j4m9bb